Categories: News

Arbor Biotechnologies to Present at 2023 Cell & Gene Meeting on the Med

CAMBRIDGE, Mass., April 06, 2023 (GLOBE NEWSWIRE) — Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that Devyn Smith, Ph.D., Arbor’s Chief Executive Officer and the Chairman of Alliance for Regenerative Medicine, will give welcoming remarks and present at the annual Cell & Gene Meeting on the Med. The congress will be held April 12-14 in Barcelona, Spain and livestreamed globally.

Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Med is a two-day conference featuring more than 60 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies, as well as over 100 panelists and featured speakers.

The following are specific details regarding Arbor Biotechnologies’ presentation at the conference:

  Event: 2023 Cell & Gene Meeting on the Med
  Date: Wednesday, April 12th
  Time: 5:45AM ET / 11:45 AM CET
  Location: Hotel Arts Barcelona
Marina 19-21
Barcelona, 08005 Spain

Virtual attendance is available which includes a livestream of Arbor Biotechnologies’ presentation and the ability to view all conference sessions on-demand. Please visit https://meetingonthemed.com/ for full information including registration.

Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Laura Stringham at lstringham@alliancerm.org and interested media should contact Stephen Majors at smajors@alliancerm.org.

About Arbor Biotechnologies®
Arbor Biotechnologies is a next-generation gene editing company focused on discovering and developing potentially curative genomic medicines, with the most extensive toolbox of proprietary genomic editors in the industry to date. Founded by Feng Zhang, David Walt, David Scott, and Winston Yan, our proprietary discovery engine is focused on discovering and evolving technologies that enable gene knockout, RT editing, precise excisions and large insertions into endogenous loci. Leveraging our wholly owned nucleases as the chassis for genetic modification, we have the unique ability to work backward from disease pathology and choose the optimal editors or combination of editors for the disease in question, with a focus on areas of high unmet need. As Arbor continues to advance its pipeline toward the clinic with an initial focus in liver and CNS disease, the Company has also secured several partnerships around gene editing and ex vivo cell therapy programs to broaden the reach of its novel nuclease technology. For more information, please visit: arbor.bio.

Contact

Media
Amy Bonanno, Solebury Strategic Communications
abonanno@soleburystrat.com
914-450-0349

Staff

Recent Posts

Modular Medical Announces Pricing of $8.2 Million Public Offering

SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular…

2 hours ago

Nicole Garrett and Under Pressure Hyperbarics Lead the Charge in Wellness Education With Immersive Events at L.A. Fashion Weekend and Beyond

BEVERLY HILLS, CALIFORNIA / ACCESSWIRE / November 21, 2024 / Nicole Garrett, CEO of Under…

5 hours ago

Beacon Healthcare Systems Expands Leadership Team with Addition of Ayman Mohamed as Chief Technology Officer

HUNTINGTON BEACH, Calif., Nov. 21, 2024 /PRNewswire/ -- Beacon Healthcare Systems, is pleased to announce…

8 hours ago

Talkiatry Ranked Number 6 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Attributes Revenue Growth to Innovative Partnerships, Strong Team, and Unique Value-Based Care Model NEW YORK,…

8 hours ago

Bright Light Imaging Leverages Alpha Nodus’s Gravity Auth, Enhanced by Integration with ADS’s MedicsRIS, to Streamline Patient Care

Automation That Makes a Difference SUNRISE, Fla., Nov. 21, 2024 /PRNewswire/ -- When it comes…

8 hours ago